Institution
Central Drug Research Institute
Facility•Lucknow, Uttar Pradesh, India•
About: Central Drug Research Institute is a facility organization based out in Lucknow, Uttar Pradesh, India. It is known for research contribution in the topics: Catalysis & Leishmania donovani. The organization has 4357 authors who have published 7257 publications receiving 143871 citations. The organization is also known as: Central Drug Research Institute, Lucknow & CDRI.
Topics: Catalysis, Leishmania donovani, Ring (chemistry), Aryl, Apoptosis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Water extract of the bark of plant of Pterocarpus marsupium Roxb is used as an antidiabetic drug in indigenous medicine in India and has insulinogenic as well as insulin like properties.
Abstract: Water extract of the bark of plant ofPterocarpus marsupium Roxb is used as an antidiabetic drug in indigenous medicine in India. (−) Epicatechin, its active principle, has been found to be insulinogenic. The presentin vitro study reports some insulin like activities of (−) epicatechin. Like insulin, (−) epicatechin stimulates oxygen uptake in fat cells and tissue slices of various organs, increases glycogen content of rat diaphragm in dose-dependent manner with corresponding increase in U14-C glucose uptake, and inhibits theophylline induced lipolysis in isolated fat pads in dose-dependent manner. Experiments on competitive binding of125I-insulin and (−) epicatechin to liver cell plasma membrane indicate that insulin does not share binding site with (−) epicatechin. (−) Epicatechin at a concentration of up to 1 mM does not effect the release of glucagon from the isletsin vitro. Thus, (−) epicatechin has insulinogenic as well as insulin like properties.
94 citations
••
TL;DR: In this paper, a library of 16 dihydropyrido[2,3d]pyrimidines was synthesized on solid support using microwave irradiation in high yields (82 and 92%).
94 citations
••
TL;DR: Looking into tumor microenvironment and focusing on nanotechnology based drug delivery aspects which have either been already or can be potentially employed in the future to target tumor associated macrophages for improved immunoadjuvant therapy of cancer.
94 citations
••
TL;DR: Novel analogues of melittin were designed by substituting the leucine residue at the "d" and "a" positions of its previously identifiedLeucine zipper motif by lesser hydrophobic alanine residue(s) in the leukine zipper sequence ofMelittin disturbed its pore-forming activity and mechanism only in hRBCs but not in the tested bacteria.
Abstract: Melittin is a good model antimicrobial peptide to understand the basis of its lytic activities against bacteria and mammalian cells. Novel analogues of melittin were designed by substituting the leucine residue(s) at the "d" and "a" positions of its previously identified leucine zipper motif. A scrambled peptide having the same composition of melittin with altered leucine zipper sequence was also designed. The analogues of melittin including the scrambled peptide showed a drastic reduction in cytotoxicity though they exhibited comparable bactericidal activities. Only melittin but not its analogues localized strongly onto hRBCs and formed pores of approximately 2.2-3.4 nm. However, melittin and its analogues localized similarly onto Escherichia coli and formed pores of varying sizes as tested onto Bacillus megaterium. The data showed that the substitution of hydrophobic leucine residue(s) by lesser hydrophobic alanine residue(s) in the leucine zipper sequence of melittin disturbed its pore-forming activity and mechanism only in hRBCs but not in the tested bacteria.
94 citations
••
TL;DR: Some of the signaling pathways related to proteasome inhibition and cell division that may help explain the basis of resistance of some cancers to proteAsome inhibitors are discussed and the need for usage of PIs in combination with traditional chemotherapy is underlined.
Abstract: Proteasomes are multicatalytic protease complexes in the cell, involved in the non-lysosomal recycling of intra-cellular proteins. Proteasomes play a critical role in regulation of cell division in both normal as well as cancer cells. In cancer cells this homeostatic function is deregulated leading to the hyperactivation of the proteasomes. Proteasome inhibitors (PIs) are a class of compounds, which either reversibly or irreversibly block the activity of proteasomes and induce cancer cell death. Interference of PIs with the ubiquitin proteasome pathway (UPP) involved in protein turnover in the cell leads to the accumulation of proteins engaged in cell cycle progression, which ultimately put a halt to cancer cell division and induce apoptosis. Upregulation of many tumor suppressor proteins involved in cell cycle arrest are known to play a role in PI induced cell cycle arrest in a variety of cancer cells. Although many PIs target the proteasomes, not all of them are effective in cancer therapy. Some cancers develop resistance against proteasome inhibition by possibly activating compensatory signaling pathways. However, the details of the activation of these pathways and their contribution to resistance to PI therapy remain obscure. Delineation of these pathways may help in checking resistance against PIs and deducing effective combinational approaches for improved treatment strategies. This review will discuss some of the signaling pathways related to proteasome inhibition and cell division that may help explain the basis of resistance of some cancers to proteasome inhibitors and underline the need for usage of PIs in combination with traditional chemotherapy.
94 citations
Authors
Showing all 4385 results
Name | H-index | Papers | Citations |
---|---|---|---|
Sanjay Kumar | 120 | 2052 | 82620 |
John A. Katzenellenbogen | 95 | 691 | 36132 |
Brajesh K. Singh | 83 | 401 | 24101 |
Gaurav Sharma | 82 | 1244 | 31482 |
Sudhir Kumar | 82 | 524 | 216349 |
Pramod K. Srivastava | 79 | 390 | 27330 |
Mohan K. Raizada | 75 | 473 | 21452 |
Syed F. Ali | 71 | 446 | 18669 |
Ravi Shankar | 66 | 672 | 19326 |
Ramesh Chandra | 66 | 620 | 16293 |
Manoj Kumar | 65 | 408 | 16838 |
Manish Kumar | 61 | 1425 | 21762 |
Anil Kumar Saxena | 58 | 310 | 10107 |
Sanjay Krishna | 56 | 624 | 13731 |
Naibedya Chattopadhyay | 56 | 242 | 9795 |